Brokerages expect that Core Laboratories (NYSE:CLB) will post $169.02 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Core Laboratories’ earnings. The highest sales estimate is $170.2 million and the lowest is $167.84 million. Core Laboratories posted sales of $148.07 million during the same quarter last year, which suggests a positive year over year growth rate of 14.1%. The company is expected to issue its next earnings results on Wednesday, July 19th.

According to Zacks, analysts expect that Core Laboratories will report full-year sales of $169.02 million for the current fiscal year, with estimates ranging from $634.9 million to $709.43 million. For the next year, analysts anticipate that the firm will report sales of $804.03 million per share, with estimates ranging from $712.1 million to $883.97 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Core Laboratories.

Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, April 19th. The oil and gas company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.03. Core Laboratories had a return on equity of 65.65% and a net margin of 10.74%. The company had revenue of $157.81 million for the quarter, compared to the consensus estimate of $150.44 million. During the same quarter in the prior year, the company earned $0.37 earnings per share. Core Laboratories’s revenue was up 2.7% on a year-over-year basis.

A number of analysts have commented on CLB shares. Scotiabank set a $133.00 price target on Core Laboratories and gave the stock a “hold” rating in a research report on Wednesday, March 22nd. Loop Capital raised Core Laboratories from a “hold” rating to a “buy” rating and lifted their price target for the stock from $125.00 to $130.00 in a research report on Friday, April 21st. Zacks Investment Research cut Core Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, March 3rd. Citigroup Inc reaffirmed a “neutral” rating and set a $117.00 price target (down previously from $119.00) on shares of Core Laboratories in a research report on Saturday, March 11th. Finally, ABN Amro raised Core Laboratories to a “hold” rating in a research report on Friday, April 21st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company’s stock. Core Laboratories presently has a consensus rating of “Hold” and a consensus target price of $125.60.

COPYRIGHT VIOLATION NOTICE: “Core Laboratories (CLB) Expected to Post Quarterly Sales of $169.02 Million” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/05/26/core-laboratories-clb-expected-to-post-quarterly-sales-of-169-02-million.html.

Institutional investors have recently modified their holdings of the stock. Achmea Investment Management B.V. bought a new position in shares of Core Laboratories during the first quarter valued at about $245,000. Goldman Sachs Group Inc. boosted its position in shares of Core Laboratories by 156.2% in the first quarter. Goldman Sachs Group Inc. now owns 68,823 shares of the oil and gas company’s stock valued at $7,951,000 after buying an additional 41,955 shares during the period. Ashford Capital Management Inc. boosted its position in shares of Core Laboratories by 6.5% in the first quarter. Ashford Capital Management Inc. now owns 17,924 shares of the oil and gas company’s stock valued at $2,071,000 after buying an additional 1,097 shares during the period. FNY Managed Accounts LLC bought a new position in shares of Core Laboratories during the first quarter valued at about $123,000. Finally, HighTower Advisors LLC boosted its position in shares of Core Laboratories by 155.4% in the first quarter. HighTower Advisors LLC now owns 9,579 shares of the oil and gas company’s stock valued at $1,100,000 after buying an additional 5,829 shares during the period.

Core Laboratories (NYSE:CLB) traded up 2.79% on Friday, reaching $102.87. The company’s stock had a trading volume of 542,672 shares. Core Laboratories has a 1-year low of $96.30 and a 1-year high of $133.38. The company has a market capitalization of $4.55 billion, a price-to-earnings ratio of 68.13 and a beta of 1.55. The firm’s 50 day moving average price is $110.76 and its 200-day moving average price is $113.93.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, May 23rd. Stockholders of record on Friday, April 28th were issued a $0.55 dividend. The ex-dividend date of this dividend was Thursday, April 27th. This represents a $2.20 annualized dividend and a dividend yield of 2.20%. Core Laboratories’s dividend payout ratio (DPR) is presently 150.68%.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

12 Month Chart for NYSE:CLB

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.